Background
Introduction
Despite improved clinical strategies for the treatment of non-Hodgkin s lymphomas, relapse rate still remains elevated. The advent of ' monoclononal antibodies, rituximab in particular, has revolutionized the clinical prognosis of low-grade lymphomas, leading to clinical responses in a substantial proportion of patients, and adds to the armament of conventional chemo-and radiotherapy. However, disease relapses occur because of acquired resistance to the original and ensuing treatments. There is a need for new strategies, and cellular immunotherapy could provide such a complementary approach by recruiting effectors of the adaptive immune system against tumors.
Although a growing number of tumor-associated antigens has been discovered in the last decade, particularly in melanoma, very few tumor antigens are known in non-Hodgkin s lymphomas. The tumor Ig idiotype has already been used successfully in clinical trials , .
The reverse immunology methodology has defined the catalytic subunit of telomerase as a potential shared tumor antigen , but its [3] immunological significance has still to be examined in a vaccination setting. Therefore, an alternative strategy in these malignancies is the use of the complete set of unknown tumor antigens, in the form of whole tumor cells. A critical parameter in this case is the capacity of the vaccine to induce cross-presentation of tumor antigens by antigen presenting cells (APC), i.e. presentation of internalized antigens in association with MHC class I molecules. In some murine models, cell-associated antigens are cross-presented with much higher efficiency in vivo and in vitro than soluble antigens . Efficient uptake of tumor-derived material by endocytosis is likely to be important. [4] [5] [6] Macrophages, and particularly immature dendritic cells can take up antigenic material from live or dead cells , , either apoptotic or [7 8 ] necrotic. It has also been shown that antigens associated with immune complexes , or opsonized cells , are efficiently [9 10] [11 12] cross-presented by dendritic cells and can be used to generate anti-tumor cytotoxic T lymphocytes, in vitro and in vivo . 2 8 In this paper, we sought to compare the different forms of human lymphoma cells for their capacity to induce cross-presentation of cellular antigens by macrophages or dendritic cells in order to determine the best way to use whole tumor cells in a cell therapeutic approach. We evaluated in particular the use of rituximab to target tumor cells toward antigen presenting cells.
Material and methods

Cells
Lymphoma B cells were prepared from invaded spleens of patients with follicular lymphoma (n 1), mantle cell lymphoma (n 2) or = = small lymphocytic lymphoma (n 1), containing more than 95 tumor cells, as assessed by CD19 and Ig light chain staining . All = % [14] patients gave informed consent to participate to this study. Malignant cells were cryopreserved in liquid nitrogen and thawed immediately before use. Viability after thawing was higher than 85 , as measured by Annexin V and Propidium iodide staining.
%
Peripheral blood was obtained from HLA-A2 healthy volunteers who gave informed consent. Peripheral blood mononuclear cells + were isolated by density-gradient centrifugation. Monocytes were purified with Rosette Sep isolation kit (Stem Cell Technologies, Meylan, France) and used to generate dendritic cells (DC) and macrophages as previously demonstrated. Dendritic cells were generated by a six-day culture in RPMI medium supplemented with 10 decomplemented fetal calf serum, GM-CSF (500 U/ml, Leucomax, % Schering-Plough, France) and IL-4 (10 ng/ml, Peprotech, Le Perray en Yvelines, France). Macrophages were generated in Iscove medium supplemented with 10 decomplemented fetal calf serum and GM-CSF (500 U/ml), as described previously . At the end of the culture, % [15] dendritic cells were 100 CD1a , CD14-and CD83-and macrophages were 100 CD14 and CD64 . 
+ γ
Because peripheral blood cells from patients were not available, we used antigen-presenting cells from normal donors and tumor cells from patients in the following experiments.
Microscopy study
Lymphoma B cells were prepared as previously described . They were left untreated or incubated for 30 min at 56 C to induce 
Flow cytometric measurement of tumor cell uptake
Lymphoma B cells labeled with PKH26 (Sigma, 2 mol.L , 20 C, 5 min) were then prepared as previously described , to obtain
apoptotic, necrotic or opsonized tumor cells. B cells were cocultured at 4:1 ratio with the APC in RPMI 10 FCS for 2 hours, and 
Assay for cross-presentation
To demonstrate cross-presentation we used a model in which we measured the IFN secretion by specific anti-viral CD8 T cells in γ +
response to APC loaded with tumor cells containing non-replicating influenza virus. In this assay, autologous macrophages or dendritic inserm-00332094, version 1 -20 Jan 2009 3 8 cells and CD8 T cells were HLA-A2 , whereas lymphoma B cells were HLA-A2-, making tumor cells unable to directly present viral
antigens to CD8 T cells.
+
On the day before cross-presentation assay, lymphoma B cells were treated with non-replicating influenza virus and then handled as described above, to obtain necrotic, apoptotic, or opsonized cells. After extensive washing, 2500 B cells were added to 5000 APC for four hours in round-bottom wells to allow endocytosis of tumor material. Then 5.10 effector T cells were added with 100ng/ml soluble CD40 5 ligand (soluble CD40L kit, Alexis). In preliminary experiments we found that addition of sCD40L was needed for cross-presentation, as previously described . Culture supernatant was collected after 48h, and assayed for cytokine content using the Cytokine Bead Array kit [19] (Becton Dickinson) as previously described .
[16]
Results
Tumor material is efficiently taken up by macrophages and dendritic cells
To measure endocytosis of tumor-derived material by APC, which may be a limiting step for cross-presentation, we used two methods: morphological examination after cytocentrifugation of cells and MGG staining ( ) and flow cytometry ( ). Lymphoma . By morphological examination, we observed significant endocytosis of whole tumor cells by macrophages only with [18] rituximab-opsonized cells ( ) whereas only marginal endocytosis of non-treated, apoptotic and necrotic cells could be observed. We Fig. 1A did not detect any endocytosis of whole B cells by dendritic cells ( ). Fig. 1B Then, to study more precisely the internalisation of tumor derived material, we measured it by flow cytometry. Indeed, the uptake of apoptotic material may involve endocytosis or macropinocytosis of shed apoptotic corpses rather than phagocytosis of whole cells , [20] two internalization processes that may be undetectable by with MGG staining. endocytosis at 4 C indicated that it was not an artifact due to dye transfer. Consistent with a previous report , we found that° [7] antigen-presenting cells acquired cellular material from live untreated cells. Surprisingly, the extent of internalization of non-treated cells was in the same range as for uptake of apoptotic or necrotic cells.
Endocytosis of cellular material was confirmed by fluorescence microscopy. APC were stained with the green fluorescent dye PKH67, and after incubation with PKH26-stained B cells, internalization was visualized as colocalisation of dyes with yellow staining. As shown in , extensive internalization of cellular material was seen in every case. Consistent with MGG staining, phagocytosis of opsonized Fig. 3 cells by macrophages could be visualized by internalization of whole tumor cells, whereas in all other cases, internalized material consisted of small fragments.
We also examined maturation of dendritic cells after endocytosis of tumor cells. Whatever the treatment applied, dendritic cells did not mature, as assessed by CD83, HLA-DR, CD80 or CD86 staining (data not shown).
Dendritic cells are able to cross-present antigens from non-treated, apoptotic and opsonized but not from necrotic lymphoma cells
To evaluate whether these various treatments of lymphoma B cells promote cross-presentation, we used influenza virus as a surrogate tumor-associated antigen as previously described , .
[ 8 17]
We first verified the internalization of the virus by B cells, by detecting viral haemagglutinin in virus-treated lymphoma B cells. B cells expressed haemagglutinin at their surface after incubation with the virus at 37 C ( ), whereas this staining was not observed at°Fig. HLA-A2 negative, lymphoma B cells by themselves should not be able to present viral antigens to the HLA-A2 specific T cells. In these + two experiments, there were no striking differences between non-treated, apoptotic and opsonized cells for cross-presentation by dendritic cells. To ensure that virus was not released by B cells and endocytosed by APC, we incubated the overnight supernatants of the different cell preparations with dendritic cells and assessed T cell response. The absence of IFN production by anti-influenza T cells, indicates that γ neither free virus nor secreted vesicles or membrane fragments were responsible for antigen transfer (data not shown). In contrast to dendritic cells, macrophages were not able to cross-present viral antigens to anti-influenza T lymphocytes, whatever the treatment of tumor cells (data not shown).
Discussion
In this paper, we aimed to determine whether whole tumor cells from lymphoma patients could represent an alternative approach to provide antigens to antigen presenting cells in the perspective of setting-up clinical immunotherapeutic trials. We previously reported that is was feasible to purify lymphoma cells from invaded biopsies , and to prepare functional dendritic cells from patients , in [18] [ 15] conditions suitable for therapy. Here, we developed an interesting model allowing to demonstrated that human whole tumor cells can be endocytosed by antigen presenting cells and then induce activation of reactive T cells, by a cross-presentation process. These results demonstrate that whole lymphoma B cells combined to antigen presenting cells could effectively induce a cross-presentation of tumor antigens and provide rationales for such an approach in the setting-up of clinical trials.
We first measured the endocytosis of tumor cells by dendritic cells. We set-up a flow cytometric method, more accurate than microscopic observation, to take into account the endocytosis of both whole tumor cells and parts of cells such as apoptotic bodies or membrane fragments. By this means, we have shown that both DC and macrophages were very efficient at endocytosing tumor-derived material, although dendritic cells were always less endocytic, as expected. Antigen transfer from lymphoma B cells to APC likely involved close cell-to-cell interactions. Indeed, incubation with supernatants of the different tumor cells did not induce any staining of APC indicating that neither shed vesicles nor cell debris were transferred to APC. In this model, the nature of the interactions and receptors involved remains to be examined except for endocytosis of opsonized cell by macrophages which involved CD32-mediated phagocytosis as described elsewhere . Cellular transfer may consist in non-specific macropinocytosis or endocytosis of cytoplasmic material, or in [21] membrane transfer from tumor cells to APC. Such a transfer has already been described with simian cells , and with human [7] monocyte-derived dendritic cells , . [11 22] We next compared the repercussions of the different treatments on tumor antigen cross-presentation by APC. Because of the paucity of known tumor antigens in this pathology, we used an already described model , and studied cross-presentation of viral antigens after . So, antibodies against B-cell markers could improve the efficacy of using of [26] whole tumor cells in stimulating the antitumor response in vivo.
inserm-00332094, version 1 -20 Jan 2009 Cross-presentation of viral antigens by dendritic cells to CD8 T cells. Tumor cells were treated with influenza virus and either left untreated (NT), induced in apoptosis (APO), in necrosis (NEC), or opsonized by rituximab (OPS). After extensive washing, B cells were added to dendritic cells for four hours and anti-viral CD8 T cells were then added. Culture supernatant was collected after 48h, and assayed for IFN .
γ
The data of two experiments are presented.
